We are live on ! Find out more
STML

Stemline Therapeutics, Inc.
STML

Delisted

STML was delisted on the 9th of June, 2020.

69 hedge funds and large institutions have $163M invested in Stemline Therapeutics, Inc. in 2013 Q4 according to their latest regulatory filings, with 18 funds opening new positions, 21 increasing their positions, 23 reducing their positions, and 19 closing their positions.

New
Increased
Maintained
Reduced
Closed

5% less first-time investments, than exits

New positions opened: 18 | Existing positions closed: 19

9% less repeat investments, than reductions

Existing positions increased: 21 | Existing positions reduced: 23

1% less funds holding

Funds holding: 7069 (-1)

52% less capital invested

Capital invested by funds: $338M → $163M (-$175M)

Holders
69
Holders Change
-1
Holders Change %
-1.43%
% of All Funds
2%
Holding in Top 10
1
Holding in Top 10 Change
+1
Holding in Top 10 Change %
% of All Funds
0.03%
New
18
Increased
21
Reduced
23
Closed
19
Calls
Puts
Net Calls
Net Calls Change

STML Hedge Fund Activity: Q4 2013 in Review

69 of the 3,445 institutional investors tracked by Wall St. Rank reported a position in Stemline Therapeutics, Inc. (STML) for Q4 2013, worth a combined $163M — down 52% from $338M a quarter earlier.

Sellers outnumbered buyers: 19 funds closed out of STML and 18 opened new positions — a net loss of 1 holder — while 23 trimmed existing stakes and 21 added.

The largest buyer was Franklin Resources, adding an estimated $9.64M. The largest seller was Citadel Advisors, exiting entirely with an estimated $7.09M sold.

  • 69 institutional investors held Stemline Therapeutics, Inc. (STML) as of Q4 2013, down from 70 in Q3 2013.
  • Funds reported $163M of Stemline Therapeutics, Inc. stock for Q4 2013, down 52% quarter-over-quarter.
  • 18 funds opened new Stemline Therapeutics, Inc. positions in Q4 2013 and 19 closed out, a net change of -1 holder.
  • The largest Stemline Therapeutics, Inc. buyer in Q4 2013 was Franklin Resources, an estimated $9.64M added.
  • The largest Stemline Therapeutics, Inc. seller in Q4 2013 was Citadel Advisors, an estimated $7.09M sold.

Based on aggregated 13F filings for Q4 2013.